ClinicalTrials.gg
RecruitingNCT07070869SPAMLO 3 0Updated Oct 26, 2026

SPAMLO-3.0 : Having Fun Shedding Light on Darkness, a Playful Approach to Reduce Anxiety in Palliative Care

An interventional study of Serious game in Palliative Care, Serious Games and Anxiety, sponsored by Centre Hospitalier de Saint-Brieuc. Recruiting at 8 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Primary conditionAnxiety Disorders(the registry's first term)UnverifiedIs this wrong?The registry often attaches Anxiety Disorders to studies about something else, and this study's title and listed conditions do not name it. No better condition is named, so the registry's term is kept.

Sponsored by Centre Hospitalier de Saint-Brieuc · Not applicable, Interventional, and Supportive care

How we know

Updated Oct 26, 2026Now RecruitingStart date moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
280
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

End-of-life care is often accompanied by anxiety-not only for patients in palliative care, but also for their loved ones and the healthcare professionals supporting them. This anxiety may stem from a fear of death, loss of functional abilities, or a worsening of symptoms as the illness progresses.

It contributes to emotional, psychological, and physical suffering, ultimately diminishing patients' quality of life. Most data on palliative care focus on cancer patients, among whom anxiety prevalence varies greatly, but may affect more than 70% of individuals.

Currently, anxiety in palliative care patients is managed through non-pharmacological approaches (such as environmental modifications and relaxation techniques) and/or pharmacological treatments (including antidepressants, neuroleptics, and anxiolytics).

The investigators recently developed the serious game SPAMLO with the aim to present and raise awareness about palliative care. The educational scenario was built around three settings: the hospital, the home, and the nursing home (EHPAD). The participant will follow Vito, a virtual character, whose sister is receiving palliative care. Vito will explore the different types of support available, starting at the hospital. He will learn about what a collegial discussion is, the Clayes-Léonetti law, advance directives, the trusted person, as well as the specificities of pediatrics. Through home hospitalization, Vito will discover palliative care outside the hospital setting, including home adaptations with appropriate equipment and the various available support services. Finally, Vito will visit the nursing home, where topics such as oral care, respecting the patient's choices, and the importance of preserving them will be addressed.

Thanks to its playful approach and the knowledge gained, this game could help reduce anxiety in palliative care patients through non-pharmacological means. This research project has beeen co-designed with a JALMALV volunteer (Accompany life until death - french association).

Read the detailed description

Participants will be randomly assigned to two groups (at a 1:1 ratio):

Control group: standard care provided by the mobile palliative care team, according to the usual practices of the healthcare team.

Intervention group: standard care by the healthcare team plus participation in the serious game "SPAMLO-3.0."

Participants will have 7 days to complete the game (multiple sessions allowed). Participant's anxiety and secondary outcomes will be measured on Day 15 to assess the primary endpoint.

A second evaluation is planned on day 30 for secondary endpoints. This second assessment will allow participants time to reflect following their participation in the serious game, potentially encouraging the designation of a trusted person and the drafting of advance directives.

Demographic, clinical, therapeutic characteristics, and questionnaires will be collected at inclusion, Day 15, and Day30. The study duration for each participant is 30 days.

02

Conditions studied

  • Palliative Care
  • Serious Games
  • Anxiety

Browse trials for

Keywords

  • anxiety
  • serious game
  • palliative care
03

In context

Anxiety Disorders Unverified

7,249 studies on the registry are indexed under Anxiety Disorders; 1,691 are open to participants now.

This study's planned enrollment of 280 is above the median of 80 across 6,103 interventional studies indexed under Anxiety Disorders.

Browse Anxiety Disorders studies →

Lead sponsor

Centre Hospitalier de Saint-Brieuc is the lead sponsor of 9 studies on the registry; 3 are open to participants now.

Compared within Anxiety Disorders, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant for whom no curative treatment is proposed, who is either discharged home or hospitalized in palliative care
  • presumed to be greater than one month
  • No cognitive impairments, according to the healthcare team's assessment
  • Participantt has given free and
  • Participant affiliated with a social security system
  • The participant owns a computer, tablet, or smartphone with an internet connection and agrees to participate in the serious game SPAMLO-3.0.

Exclusion criteria

Exclusion Criteria:

  • Participant who is demented, confused, or in a coma
  • Fatigability, according to the healthcare team's assessment
  • Visually or hearing impaired participant, according to the healthcare team's assessment
  • No inclusion of persons targeted by Articles L. 1121-5 to L. 1121-8 and L. 1122-1-2 of the Public Health Code (e.g., minors, legally protected adults, etc.)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
280 participants (estimated)

Study arms

  • Experimental
    Intervention group

    Standard care by the healthcare team and participation in the serious game "SPAMLO-3.0."

    Behavioral: Serious game

  • No intervention
    Control group

    Standard care provided by the mobile palliative care team, according to the usual practices of the healthcare team.

Interventions

  • BehavioralSerious game

    Participation in the serious game "SPAMLO-3.0."

06

What researchers measure

Primary outcomes

  1. Hospital Anxiety and Depresion Scale

    Questionnaire completed by the participant. It consists of 14 items rated from 0 to 3. Seven questions relate to anxiety (total A) and the other seven to the depressive dimension (total D), thus allowing for the calculation of two scores (maximum score for each = 21). The scores for each of the Anxiety and Depression subscales are interpreted as follows: 0 to 7: no signs of anxiety and/or depressive disorders. 8 to 10: borderline or doubtful symptomatology. 11 to 21: confirmed anxiety and/or depressive disorders of varying severity.

    Time frame: Day 0, Day 15 and Day 30

Secondary outcomes

  1. Acceptability of the serious game through a Likert questionnaire

    Likert questionnaire completed by the participant

    Time frame: Day 30

  2. Number of participants who completed the serious game.

    Data obtained by the coordinating investigator

    Time frame: Through study completion, an average of 20 months

  3. French System Usability Scale

    Healthcare team's perception of the use of the serious game. The questionnaire includes ten items, each formulated as a statement. For each statement, the user is asked to indicate their level of agreement or disagreement using a 5-point Likert scale (1 = Strongly disagree; 5 = Strongly agree). If the user is unsure how to respond to an item, they are encouraged to answer anyway by selecting the middle point of the scale (score 3).

    Time frame: Through study completion, an average of 20 months

  4. McGill Quality of Life Questionnaire

    Completed by the participant. It is a 17-item multidimensional tool designed to measure physical well-being, physical symptoms, psychological symptoms, existential well-being and support, as well as overall quality of life. The scores for each domain are calculated separately.

    Time frame: Day 0, Day 15 and Day 30

  5. Insomnia Severity Index

    Completed by the participant. The first item assesses the intensity of insomnia complaints separately for difficulty falling asleep, maintaining sleep, and early awakening. One item evaluates the subject's overall satisfaction with their sleep, and another item assesses concerns regarding insomnia. Finally, two items evaluate the impact on daily life activities. Each item is rated by the patient from 0 to 4.The total score ranges from 0 to 28. * between 0 and 7 indicates the absence of clinically significant insomnia complaints, * between 8 and 14 indicates subclinical (mild) insomnia complaints, * between 15 and 21 indicates clinically significant (moderate) insomnia complaints, * between 22 and 28 indicates severe insomnia complaints.

    Time frame: Day 0 and Day 30

  6. Palliative Performance Scale

    Completed by investigators. This is an 11-point scale used to measure a patient's performance in 10% increments, with 100% representing health and 0% representing death. The scale is based on five observable parameters: mobility, activity level, independence in personal care, feeding, and level of consciousness.

    Time frame: Day 0, Day 15 and Day 30

  7. Visual analog scale

    Evaluated by the participant. This scale measures pain intensity on a scale from 0 to 10. The correspondence between VAS (Visual Analog Scale) levels and pain intensity is as follows: * between 1 and 3: mild pain intensity * between 3 and 5: moderate pain intensity * between 5 and 7: severe pain intensity * above 7: very severe pain

    Time frame: Day 0, Day 15 and Day 30

07

Study locations

8 of 8 sites recruiting
  • Groupe Hospitalier Rance Emeraude, site René Plevin
    Dinan, 22100, France
    Recruiting
    • Angélique DIMITRU-MARIN · Contact
  • Centre Hospitalier de Guingamp
    Guingamp, 22200, France
    Recruiting
    • Etienne BAUDRY, Dr · Contact
  • Centre Hospitalier de Lannion - Trestel
    Lannion, 22300, France
    Recruiting
    • Johann COSTE, Dr · Contact
  • Centre Hospitalier Centre Bretagne
    Noyal-Pontivy, 56920, France
    Recruiting
    • Radu-Ioan VANICA, Dr · Contact
  • Centre Hopsitalier de Saint-Brieuc - Paimpol - Tréguier, site de Paimpol
    Paimpol, 22500, France
    Recruiting
    • Pierre KERGARAVAT, Dr · Contact
  • Centre Hospitalier Universitaire de Rennes, site de la Tauvrais
    Rennes, 35000, France
    Recruiting
    • Vincent MOREL, Pr · Contact
  • Centre Hospitalier de Saint-Brieuc - Paimpol - Tréguier, site de Saint-Brieuc
    Saint-Brieuc, 22000, France
    Recruiting
  • HAD du Pays Briochin - Fondation AUB Santé
    Saint-Brieuc, 22000, France
    Recruiting
    • Jimmy SOLO · Contact
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2027; primary completion for Jul 2027, 0 months later.

Of 3,871 non-industry interventional studies with no phase under Anxiety Disorders, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 28. This study's planned 0 months is below that.

Counting every sponsor, half of 3,976 studies reached it within 12 months; a quarter within 5 and three quarters within 28.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: start Jul 2025 → Jul 2027, primary completion Apr 2027 → Jul 2027 and completion Apr 2027 → Jul 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2025
First posted
Jul 17, 2025
StartEst.
Jul 2027was Jul 2025
Primary completionEst.
Jul 2027was Apr 2027
CompletionEst.
Jul 2027was Apr 2027
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 26, 2026
Sites
8 sites added, 1 site removed
Show 8 added (8 France)
  • Groupe Hospitalier Rance Emeraude, site René Plevin · Dinan, France
  • Centre Hospitalier de Guingamp · Guingamp, France
  • Centre Hospitalier de Lannion - Trestel · Lannion, France
  • Centre Hospitalier Centre Bretagne · Noyal-Pontivy, France
  • Centre Hopsitalier de Saint-Brieuc - Paimpol - Tréguier, site de Paimpol · Paimpol, France
  • Centre Hospitalier Universitaire de Rennes, site de la Tauvrais · Rennes, France
  • Centre Hospitalier de Saint-Brieuc - Paimpol - Tréguier, site de Saint-Brieuc · Saint-Brieuc, France
  • HAD du Pays Briochin - Fondation AUB Santé · Saint-Brieuc, France
Show 1 removed
  • Centre Hospitalier de Saint-Brieuc - Paimpol - Tréguier · Saint-Brieuc, France
Oct 26, 2026
Start date
Jul 2025→Jul 2027
Oct 26, 2026
Primary completion
Apr 2027→Jul 2027
Oct 26, 2026
Study completion
Apr 2027→Jul 2027
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Not yet recruiting→Recruiting
    8 sites added, 1 site removed
    Show 8 added (8 France)
    • Groupe Hospitalier Rance Emeraude, site René Plevin · Dinan, France
    • Centre Hospitalier de Guingamp · Guingamp, France
    • Centre Hospitalier de Lannion - Trestel · Lannion, France
    • Centre Hospitalier Centre Bretagne · Noyal-Pontivy, France
    • Centre Hopsitalier de Saint-Brieuc - Paimpol - Tréguier, site de Paimpol · Paimpol, France
    • Centre Hospitalier Universitaire de Rennes, site de la Tauvrais · Rennes, France
    • Centre Hospitalier de Saint-Brieuc - Paimpol - Tréguier, site de Saint-Brieuc · Saint-Brieuc, France
    • HAD du Pays Briochin - Fondation AUB Santé · Saint-Brieuc, France
    Show 1 removed
    • Centre Hospitalier de Saint-Brieuc - Paimpol - Tréguier · Saint-Brieuc, France
    Start date Jul 2025→Jul 2027
    Primary completion Apr 2027→Jul 2027
    Study completion Apr 2027→Jul 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07070869
Lead sponsor
Centre Hospitalier de Saint-Brieuc
Responsible party
Sponsor
First posted
Jul 17, 2025
Start date
Jul 2027 (estimated)
Primary completion
Jul 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Oct 26, 2026

Study contacts

Fanny BEGUIER
Contact
fanny.beguier@armorsante.bzh
0296018165 ext. +33
Stéphanie LOUICHE
principal investigator · Centre Hospitalier de Saint-Brieuc - Paimpol - Tréguier

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion